NMT Medical Inc.(fka NMTI)

[trader53]

NMT Medical, Inc. will sell its BioTREK technology platform


, which has been assigned to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors, at its sealed bid sale of June 10, 2011.

BioTREK is a technology platform that utilizes a novel bioabsorbable polymer to create a family of percutaneous devices for repair or remodeling of intracardiac defects including patent foramen ovale (PFO), atrial septal defect (ASD) and left atrial appendage (LAA). Unlike other bioabsorbable cardiac implants, BioTREK implants are rendered radiopaque for fluoroscopic visualization using a proprietary technology developed by NMT Medical.

The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, June 10, 2011 at noon. Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - [e-mail] or 781-237-8840. They will then receive a bid package.

http://www.otcmarkets.com/stock/NMTI/news